Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular Carcinoma

Дата публикации: 01-10-2026 00:00:00

This cohort study examines the association of an immune checkpoint inhibitor–based multimodal pretransplant strategy with posttransplant oncologic outcomes and acute rejection among patients with hepatocellular carcinoma that was initially beyond the Milan criteria who underwent liver transplant.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases	0	7	03-07-2026
2	Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma	0	5.96	30-07-2026
3	Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	0	11.9	01-07-2026
4	Common cholesterol drug may improve the effectiveness of immunotherapy in liver cancer patients	0	6.12	21-09-2026
5	Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score of Less Than 1	0	12.19	17-09-2026
6	MASH Comorbidity Burden and Overall, Waiting List, and Post–Liver Transplant Mortality	0	8.64	05-08-2026
7	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
8	Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	0	14.62	23-07-2026
9	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.13. Источник: jamanetwork.com.